Impact of Biologic Therapy on Key Cardiovascular Risk Parameters in a Psoriatic Cohort—a Retrospective Review
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
Impact of Biologic Therapy on Key Cardiovascular Risk Parameters in a Psoriatic Cohort—a Retrospective Review ; volume:14 ; number:5 ; day:25 ; month:4 ; year:2024 ; pages:1337-1348 ; date:5.2024
Dermatology and therapy ; 14, Heft 5 (25.4.2024), 1337-1348, 5.2024
- Creator
-
Joseph, Joseph
Truong, Kelvin
Lo, Serigne N.
Foo, Fiona
Zaman, Sarah
Chow, Clara K.
Smith, Annika
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s13555-024-01154-8
- URN
-
urn:nbn:de:101:1-2408020946296.285415168855
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:50 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Joseph, Joseph
- Truong, Kelvin
- Lo, Serigne N.
- Foo, Fiona
- Zaman, Sarah
- Chow, Clara K.
- Smith, Annika
- SpringerLink (Online service)
Other Objects (12)
Cardiovascular Comorbidities in Psoriatic Disease
Itolizumab – A New Biologic for Management of Psoriasis and Psoriatic Arthritis
Economic impact of biologic utilization patterns in patients with psoriatic arthritis
Treatment Switch Patterns and Healthcare Costs in Biologic-Naive Patients with Psoriatic Arthritis
Disease activity and biologic use in patients with psoriatic arthritis or rheumatoid arthritis
Real-World Treatment Persistence with Biologic Disease-Modifying Antirheumatic Drugs Among German Patients with Psoriatic Arthritis—A Retrospective Database Study
Treatment patterns and costs for anti-TNFα biologic therapy in patients with psoriatic arthritis
Treatment patterns in psoriatic arthritis patients newly initiated on oral nonbiologic or biologic disease-modifying antirheumatic drugs
Anti-inflammatory effect of biologic therapy in patients with psoriatic disease: A prospective cohort FDG PET study
Economic Burden of Switching to Different Biologic Therapies Among Tumor Necrosis Factor Inhibitor-Experienced Patients with Psoriatic Arthritis
Apremilast for biologic-naïve, peripheral psoriatic arthritis, including patients with early disease: results from the APROACH observational prospective study
Evaluating the cost-effectiveness of biologic treatments for psoriatic arthritis: can we make better use of patient data registries?
Cardiovascular Comorbidities in Psoriatic Disease
Itolizumab – A New Biologic for Management of Psoriasis and Psoriatic Arthritis
Economic impact of biologic utilization patterns in patients with psoriatic arthritis
Treatment Switch Patterns and Healthcare Costs in Biologic-Naive Patients with Psoriatic Arthritis
Disease activity and biologic use in patients with psoriatic arthritis or rheumatoid arthritis
Real-World Treatment Persistence with Biologic Disease-Modifying Antirheumatic Drugs Among German Patients with Psoriatic Arthritis—A Retrospective Database Study
Treatment patterns and costs for anti-TNFα biologic therapy in patients with psoriatic arthritis
Treatment patterns in psoriatic arthritis patients newly initiated on oral nonbiologic or biologic disease-modifying antirheumatic drugs
Anti-inflammatory effect of biologic therapy in patients with psoriatic disease: A prospective cohort FDG PET study
Economic Burden of Switching to Different Biologic Therapies Among Tumor Necrosis Factor Inhibitor-Experienced Patients with Psoriatic Arthritis
Apremilast for biologic-naïve, peripheral psoriatic arthritis, including patients with early disease: results from the APROACH observational prospective study
Evaluating the cost-effectiveness of biologic treatments for psoriatic arthritis: can we make better use of patient data registries?
Cardiovascular Comorbidities in Psoriatic Disease
Itolizumab – A New Biologic for Management of Psoriasis and Psoriatic Arthritis
Economic impact of biologic utilization patterns in patients with psoriatic arthritis
Treatment Switch Patterns and Healthcare Costs in Biologic-Naive Patients with Psoriatic Arthritis
Disease activity and biologic use in patients with psoriatic arthritis or rheumatoid arthritis
Real-World Treatment Persistence with Biologic Disease-Modifying Antirheumatic Drugs Among German Patients with Psoriatic Arthritis—A Retrospective Database Study
Treatment patterns and costs for anti-TNFα biologic therapy in patients with psoriatic arthritis
Treatment patterns in psoriatic arthritis patients newly initiated on oral nonbiologic or biologic disease-modifying antirheumatic drugs
Anti-inflammatory effect of biologic therapy in patients with psoriatic disease: A prospective cohort FDG PET study
Economic Burden of Switching to Different Biologic Therapies Among Tumor Necrosis Factor Inhibitor-Experienced Patients with Psoriatic Arthritis
Apremilast for biologic-naïve, peripheral psoriatic arthritis, including patients with early disease: results from the APROACH observational prospective study